Stewart I C, Rhind G B, Power J T, Flenley D C, Douglas N J
Department of Respiratory Medicine, University of Edinburgh, City Hospital.
Thorax. 1987 Oct;42(10):797-800. doi: 10.1136/thx.42.10.797.
The effect of an oral sustained release beta 2 agonist on symptoms, sleep quality, and peak flow rates has been studied in nine patients with nocturnal asthma. Patients received oral terbutaline 7.5 mg twice daily or placebo for seven days in a double blind crossover study and spent the last two nights of each limb in a sleep laboratory. Oral terbutaline improved morning peak flow (259 v 213 l min-1) and decreased nocturnal inhaler usage (1.3 v 1.9) with no alteration in sleep quality as assessed electroencephalographically. The study shows that oral sustained release terbutaline can be useful in the treatment of nocturnal asthma without impairment of sleep quality.
对9例夜间哮喘患者研究了口服长效β2激动剂对症状、睡眠质量和呼气峰值流速的影响。在一项双盲交叉研究中，患者每日两次口服7.5毫克特布他林或安慰剂，为期7天，并在每个阶段的最后两晚在睡眠实验室度过。口服特布他林改善了早晨的呼气峰值流速（259对213升/分钟），减少了夜间吸入器的使用次数（1.3对1.9），且经脑电图评估睡眠质量无变化。该研究表明，口服长效特布他林可有效治疗夜间哮喘，且不损害睡眠质量。
